anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The list of medications that prolong the QT interval and can provoke torsade de pointes keeps expanding. This list includes not only antiarrhythmic drugs, but also medications with no cardiac indications (like several antibiotics, antihistamines or antipsychotic medications). All these medications prolong the QT interval because they block a specific potassium channel on the myocardial cell membrane: the channel for the rapid component of the delayed rectifier potassium current or "IKr". The risk for developing torsade de pointes for patients taking any of the medications with IKr blockade capabilities varies from \>4% for antiarrhythmic drugs to \<0.01% for non-cardiac medications. The risk depends on the strength of IKr blockade, but also on specific patient characteristics. In fact, the majority of patients who develop torsade de pointes from non-cardiac medications have identifiable risk factors. In this regard, patients with a congenital long QT syndrome (LQTS) are prone to develop torsade de pointes when treated with QT-prolonging medications. This is because, due to their genetically defective ion channels, patients with LQTS have impaired ventricular repolarization and reduced "repolarization reserve." Therefore, it is common medical practice to strongly advise patients with congenital LQTS to avoid all medications that have IKr channel blocker capabilities. Zitron et al reported that some flavonoids contained in pink-grapefruit juice block the IKr channel. These investigators also reported that drinking 1 liter of pink-grapefruit juice causes QT prolongation in healthy volunteers. The magnitude of the QT prolongation provoked by grapefruit juice was small (12.5 ± 4.2 msec). However, drugs causing minor QT prolongation in healthy volunteers may provoke major QT prolongation in rare or sick individuals who are then at risk for developing torsade de pointes. Consequently, one could argue that, until proven otherwise, pink-grapefruit should be added to the list of "drugs" that are forbidden for patients with LQTS.

This is a single center, open-label, randomized, crossover study. Subjects will be admitted to the cardiology department on the day before the first dose and will remain there until study completion. After performing a baseline electrocardiogram and baseline blood tests (Complete Blood Count, chemistry - up to 10 ml of blood) subjects will be continuously recorded by a Holter monitor for 24 hours (baseline Holter). On the next day subjects will be randomly divided into two experimental therapies (one after the other in a random order to the same group of patients
Early detection and effective cancer treatment are critical to improving metastatic cancer cell diagnosis and management today. In particular, accurate qualitative diagnosis of metastatic cancer cell represents an important step in the diagnosis of cancer. Today, biosensors have been widely developed due to the daily need to measure different chemical and biological species. Biosensors are utilized to quantify chemical and biological phenomena by generating signals that are directly proportional to the quantity of the analyte present in the reaction. Biosensors are widely used in disease control, drug delivery, infection detection, detection of pathogenic microorganisms, and markers that indicate a specific disease in the body. These devices have been especially popular in the field of metastatic cancer cell diagnosis and treatment due to their portability, high sensitivity, high specificity, ease of use and short response time. This article examines biosensors for metastatic cancer cells. It also studies metastatic cancer cells and the mechanism of metastasis. Finally, the function of biosensors and biomarkers in metastatic cancer cells is investigated.
The present invention discloses a traditional Chinese medicine composition for treating dermatosis, which is prepared by weight from 10 to 45 parts of fructus cnidii, 10 to 45 parts of pricklyash berry, 3 to 15 parts of alum, 5 to 30 parts of kuh-seng, 5 to 35 parts of corktree bark and one or a plurality of incidental components: 5 to 25 parts of broom cypress fruit, 3 to 15 parts of Chinese gentian and 5 to 35 parts of dandelion. The components are pulverized, mixed, watered, mulled, cooled and filtered so as to obtain liquid, and the external apply medicine liquid is obtained. The present invention solves the problems of many components, complicated preparation technology, poor curative effect, etc. of the traditional Chinese medicine composition for treating dermatosis. The prevent invention has the advantages of obvious curative effect, reasonable compatibility and adding amount, few components, simple manufacture, convenient use, broad application, etc. The effective rate for treating dermatitis is more than 98 %. The traditional Chinese medicine composition for treating dermatosis can be used for treating eczema, skin rash, scabies, skin allergy, itch of skin, dermatitis, beriberi, mosquito bite, swelling of vulva, pruritus vulva, internal and external pathopyretic carbuncle, etc.
FIELD: medicine. ^ SUBSTANCE: invention is referred to the field of medicine, namely to dermatovenerology and immunology and can be used for treatment of patients with sexually transmitted urogenital infections caused by chlamydiae and/or micoplasma. It includes the infusion of antibiotics of macrolides group or immunotropic drug that is selected individually, for which purpose the sensitivity of patient to immunotropic drugs is determined. That is done by in vitro definition of interferons in the samples of peripheral blood and urogenital scrapings before and after addition of each studies drug. As the result the immunotropic drug selected for treatment is the one that induces the increase of interferon activity in studied material by no less than 4 U/ml compared to the baseline level in the samples of peripheral blood and urogenital scrapings. ^ EFFECT: method provides for etiologic recovery, prevention of disease relapses, particularly due to effective interferons production on systemic and local level. ^ 1 dwg, 4 tbl, 5 ex
Recurrence of Bipolar I (BP I) major depressive episode (MDE), is now recognized as a major mental health problem. Recurrent BP I MDE is a disorder with no satisfactory therapy, and its treatment remains a challenge to clinicians. To date, initial and long-term therapy of BP I MDE has been based on un-validated practice guidelines. These guidelines recommend limiting antidepressant drug (AD) use during initial therapy of BP I MDE, and completely avoiding AD use during long-term therapy. There is, however, no empirical evidence to suggest that mood stabilizer (MS) monotherapy is superior to combined MS plus AD therapy in preventing recurrent BP I MDE. Nor is there evidence to suggest that long-term MS plus AD therapy results in more manic switch episodes. We present evidence that AD-induced mania during long-term therapy of BP I MDE has been over-estimated, and that long-term use of MS plus AD therapy may be superior to MS therapy alone in preventing recurrent BP I MDE. In this study, we will ask: "Does continuation therapy with combined lithium plus fluoxetine result in fewer MDE relapses and recurrences vs. lithium monotherapy?" To answer this question, patients with BP I MDE will receive combined lithium plus fluoxetine therapy for 8 weeks. Responders who stay well for an additional 4 weeks of consolidation therapy will then be randomized to double-blind continuation therapy with either (i) combined lithium plus fluoxetine, or (ii) lithium alone (following fluoxetine taper and discontinuation) for an additional 50 weeks. We hypothesize that long-term lithium plus fluoxetine therapy will result in fewer MDE relapses and recurrences vs. lithium monotherapy. We will also ask: "What is the relative safety, tolerability, and frequency of syndromal and sub-syndromal manic, hypomanic, and mixed state conversions during continuation treatment with combined lithium plus fluoxetine vs. lithium monotherapy?" To answer this question, we will measure: the frequency, severity, and duration of syndromal and sub-syndromal manic, hypomanic, and mixed state conversions; frequency, severity, and duration of treatment-emergent adverse events; frequency of treatment discontinuation; time to onset of first syndromal and sub-syndromal conversion event; time to first treatment intervention of each syndromal and sub-syndromal conversion event; and, time to onset of increase in suicidal ideation event. We hypothesize that lithium plus fluoxetine therapy will result in a similar frequency of syndromal and sub-syndromal conversion events, and a similar frequency of treatment-emergent adverse events. We further hypothesize that lithium plus fluoxetine therapy will result in fewer suicide ideation events and fewer study discontinuations vs. lithium monotherapy. We believe that the results of this trial may have an important public health impact on the current practice guidelines for treating BP I MDE.
The present invention relates to a traditional Chinese medicine preparation for curing coronary heart disease and angina pectoris, which is characterized in that the present invention is prepared from the following medicinal ingredients: red ginseng, milkvetch root, epimedium herb, corydalis tuber, etc. The present invention can be made into tablets, capsules, granules, oral medicinal liquids, etc. and has the functions of benefiting the heart, replenishing Qi, remoistening blood stasis and alleviating pain. In clinic, the total effective rate for curing angina pectoris is 80.0%, the total effective rate for curing EKG is 65.0%, the total effective rate for curing the symptoms of traditional Chinese medicine, such as chest pain, chest distress, palpitation, short breath, neurolysis, hypodynamia, etc., is 90.0%, the withdrawal rate of nitrate medicine is 40.0%, and the decrement rate of nitrate medicine is 80.0%. In clinical observation, no adverse reaction is discovered. The present invention is an ideal medicine for curing coronary heart disease and angina pectoris.
This invention relates to cross-linking pachyman, its preparation method and application. The cross-linking pachyman is prepared as follows: pachyman is mixed with two to five-fold mass of water or alcohol to form a mixture and the pH value is adjusted to 9~11. Epichlorohydrin with a mass 0.1~0.5% of pachyman is added and the cross-linking reaction is kept at 35~45 deg. C for 6~10 hours. The mixture is then neutralized, filtered, washed and lyophilized to obtain cross-linking pachyman. The cross-linking pachyman in this invention has good fluidity, strong water-absorption, high bulk density and dilatability and can be used as efficient disintegrating reagent. The cross-linking pachyman is homogeneously dispersed into powders during disintegration so that the disintegrating ability of the troches is enhanced and the disintegrating efficiency is promoted.
Breast loss causes negative influence on women physically, psychologically and socially. Breast prosthesis can improve patient's figure externally, increase self-confidence, thus improving quality of life. Prospective study of different breast prostheses has not yet been performed in China. The objective was to understand the knowledge regarding breast prostheses in breast cancer patients, evaluate the quality of life of patients wearing different types of breast prostheses and to compare the physical and psychological effects of different temperature-controlled breast prostheses on patients. The investigators designed a randomized control study in one cancer center in Shanghai. Eligible participants were randomized into either intervention or control group. In the first 6 weeks of the study, self-adhesive breast prostheses and conventional breast prostheses were used in the intervention and control group, respectively. In the later 6 weeks, the breast prostheses used were switched into another kind. Several dimensional parameters were examined by different questionnaires at the end of both 6th and 12th week including scars and skin, survey of breast prosthesis knowledge, survey assessing the comfort and practicality of breast prostheses, quality of life instruments for cancer patients and body image scale. The investigators expected that women would be satisfied with the temperature-controlled breast prosthesis and were more willing to choose self-adhesive breast prostheses.
Multiple myeloma is an incurable, malignant, plasma cell disorder that accounts for approximately 18 percent (%) of hematological malignancies, making it the second most common hematologic malignancy. Talquetamab (also known as JNJ-64407564) is a humanized immunoglobulin G4 (IgG4) bispecific antibody designed to target G Protein-coupled receptor family C group 5 member D (GPRC5D+) cells and cluster of differentiation 3 (CD3) receptor complex on T-cells. Belantamab mafodotin is a humanized B-cell maturation antigen (BCMA)-targeting monoclonal antibody (mAb) conjugated to a cytotoxic agent maleimidocaproyl monomethyl auristatin F (MMAF) which disrupts the microtubule network, leading to cell cycle arrest and apoptosis. This study will investigate the possible improvement of ORR or PFS with talquetamab compared with belantamab mafodotin in participants with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 mAb (alone or in combination), and whose disease is refractory to at least one proteasome inhibitor (PI) and one immunomodulatory drug (IMiD). The study will consists of a screening phase, treatment phase (until confirmed progressive disease, start of subsequent antimyeloma therapy, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first), and post-treatment follow-up phase (until death, withdrawal of consent, loss to follow-up, or end of the study, whichever occurs first). Safety evaluations will include a review of adverse events, physical examinations, eastern cooperative oncology group (ECOG) performance status, clinical laboratory tests, and vital signs.
INTRODUCTION: Vagal nerve stimulator (VNS) implantation is a vital therapy for epilepsy refractory to other treatments; however, it is associated with a very high rate of voice changes. Relatively few of these patients are evaluated for vocal fold motion impairments. In this series, we evaluate 5 such patients with a novel phenotype of forced abduction with VNS stimulation.
METHODS: Retrospective case series.
RESULTS: Five patients with a VNS implant who underwent operative direct or in-office rigid laryngoscopy and had vocal fold motion impairment associated with VNS activation are included. All 5 patients had vocal fold mobility with VNS off and a fixed with activation. All patients exhibited vocal fold abduction with VNS activation. Patient 2 has since undergone laryngeal reinnervation, which helped her intermittent dysphonia but left a small glottic gap. A type 1 thyroplasty corrected this gap and improved her voice further. Patient 3 has undergone laryngeal reinnervation for which early results show improvement in perceptual and patient reported outcomes. Patients 4 and 5 have both undergone laryngeal reinnervation with improvement in voice.
CONCLUSION: Previous reported cases of stimulated immobility associated with VNS use describe only adduction of the vocal fold. This series expands the previous work showing the VNS activation can also cause stimulated immobility in an abducted position, for which reinnervation and other medialization procedures offer promising treatment.
RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.
FIELD: biotechnology, natural compounds. SUBSTANCE: method involves preparing sap and an aqueous extract from fresh tubers and husks or dried milled tubers. The latter are obtained by mixing the dried milled tubers with hot water at ratio 1:6, kept at 70 C for 12 h and extraction is carried out at 80 C. An aqueous extract is separated, extracted three times ageing with water at ratio 1:4 for 40 min followed by extracts combining. Purification of sap diluted with water (1:1) obtained from husk aqueous extractions or dried tubers is carried out with calcium carbonate at 85 C or 80 C for 1 h for sap and husks and dried tubers, respectively. Extracts are filtered, filtrates are evaporated and crystallization of crude inulin is carried out at 4 C into cooling for 5 days from aqueous extracts after alcohol addition at ratio 1:1 or from the diluted sap. Inulin precipitates are separated and dissolved in hot water at 75 C. Additional purification involves stages using anionite, aluminium oxide, calcium carbonate followed by purification using cationite and anionite. Inulin is crystallized and reprecipitated from an aqueous-alcohol mixture (1:3) at 4 C for 24 h into cooling. Obtained product is dried and milled. EFFECT: simplified technology of inulin purification, standardized the end product. 4 cl, 2 ex
Systems and methods for estimating lifestyle metrics with a wearable electronic device are disclosed herein, and relate to wearable activity monitoring devices. One disclosed system may include a wearable electronic device (10) in the form of a wristwatch that includes a processor (60) and a sensor system that provides input to the processor (60). The sensor system may include a high power sensor (62), such as a GPS or heart rate sensor, and a low power sensor (64), such as an accelerometer. The processor (60) may operate in a high power mode in which both sensors are operable and a low power mode in which the high power sensor is not operable. In the high power mode, the processor may calculate a lifestyle metric, such as a total distance traveled, with respect to the user for a first time period based on the first data from the high power sensor. In the low power mode, the processor may calculate a lifestyle metric for a second time period based on the second data from the low power sensor and the first data and/or a derivative of the first data. In other words, in the high power mode, the device (10) uses GPS and accelerometers to calibrate stride length and measure total travel distance. In the low power mode, the GPS is not operable and the device measures the distance traveled using only the accelerometer and calibrated stride length.
PURPOSE: To provide a cosmetic and/or pharmaceutical compsn. to protect human or animal tissues, especially epithelium from damages due to contact with heavy metals. CONSTITUTION: This compsn. contains a metal ion sealing component which consists of a metal-bondable peptide having cysteine residues in a high proportion and can bond metal ions, and a physiologically inactive carrier suitable for local medication. The metal bondable peptide preferably contains 25 to 50% cysteine residues, especially 25 to 45% based on the whole number of residues, and preferably includes ligands which can form metal thiolate clusters with heavy metal ions. For example, metallothioneine, especially apometallothioneine having substantially no heavy metal ions is preferable. The amt. of the metal bondable peptide is preferably 0.01 to 10 wt.% of the whole weight of the compsn., and especially 0.1 to 5 wt.%.  The compsn. is applied before the skin is exposed to heavy metals, and then washed to remove the residue of the compd. which traps heavy metals from the skin as to prevent absorption of heavy metals on the skin.
Tropical diseases are active in South America and measures need to be taken to control these diseases. Sanitation is a major contributing factor as it serves for an ideal breeding ground for vectors. The EPA regulates water contamination and states that a water source can be recognized as contaminated if it contains anything above zero total coliforms. The severity of the water contamination within Peru can be observed by the presence of thermotolerant coliforms in 48% of all water samples. Studies have also found that on 23% of hands, 16% of utensils, and 4% of meals, E. coli was present. The most frequently contaminated item was kitchen cloths in which 89% had coliforms and 42% with E. coli. In 33% of drinking water, 27% of meals, and 23% kitchen utensils, diarrheagenic E. coli was present.

The purpose behind the research being conducted is to assist Peru concerning various factors in order to facilitate the process of working towards the reduction or complete elimination of tropical disease infections such as Dengue, Zika, and Chikungunya. The reason Peru has been identified as being the focal point for the proposed research lies within the factors that surround Peru. Peru is considered a developing country and with that encompasses consequential issues. These issues can manifest in malnutrition, disease ridden environments, debilitating physical repercussions, and many other linked issues.5 Peru also has a substantial market in which producers partake in sugar cane cultivation. "In Peru, Maple Energy anticipates that in 2013, it will harvest 1.075 million gross tons of sugar cane from its plantation for ethanol production." This is significant considering that sugar cane and molasses production attracts mosquitoes and creates a prime nesting ground for mosquitos considering the product as well as the climate which is required to grow these items. The fact that Dengue is so rampant in Peru presents the great possibility that the masking of other infections with similar symptoms such as Chikungunya and Zika is present. Given that Peru is a developing country makes this fact even more feasible considering the minimal access to quality healthcare in many locations, especially rural communities. The location of Peru gives rise to believe that many patients go undiagnosed or misdiagnosed since Peru borders Brazil, in which currently Zika and Chikungunya are currently epidemics sweeping the country. The lack of mandated hygienic practices allows the circulation of many diseases to fester and plague the Peruvian society.
The starting dose was oxycodone CR 10 mg twice daily for 3 days. The dose was then increased to 20 mg oxycodone CR twice daily for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days. Dose decreases were allowed without time restrictions.
A process for the fractionation of valuable fractions from cereal brans (e.g.  wheat, barley and oat brans, and rice polish) is described. In particular, this invention describes a two step process, in which the said bran is first subjected to a combination of enzymatic treatment and wet milling, followed by sequential centrifugation and ultrafiltration, which aims at physically separating the main bran factions, i.e. insoluble phase (pericarp and aleurone layer), germ-rich fraction, residual endosperm fraction and soluble sugars. A  second step consists of fractionating cereal brans substantially free of soluble compounds, hence insoluble phase from the above-mentioned first step, by enzymatic treatment with xylanases and/or beta-glucanase and wet milling, followed by sequential centrifugation and ultrafiltration, which aims at physically separating the main fractions, i.e. insoluble phase (remaining cell wall components), protein-rich fraction, soluble hemicellulose and oligosaccharide, and therefore maximizes the extraction rate of valuable cell wall components and aleurone cells from previously cleaned bran.